If you have been reading about 瑞他鲁肽 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-04. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Several imaging methods can be used to assess the anatomy and function of the heart, including ultrasound (echocardiography), angiography, CT, MRI, and PET, scans. An echocardiogram is an ultrasound of the heart used to measure the heart's function, assess for valve disease, and look for any abnormalities. Echocardiography can be conducted by a probe on the chest (transthoracic), or by a probe in the esophagus (transesophageal). A typical echocardiography report will include information about the width of the valves noting any stenosis, whether there is any backflow of blood (regurgitation) and information about the blood volumes at the end of systole and diastole, including an ejection fraction, which describes how much blood is ejected from the left and right ventricles after systole. Ejection fraction can then be obtained by dividing the volume ejected by the heart (stroke volume) by the volume of the filled heart (end-diastolic volume). Echocardiograms can also be conducted under circumstances when the body is more stressed, in order to examine for signs of lack of blood supply. This cardiac stress test involves either direct exercise, or where this is not possible, injection of a drug such as dobutamine. CT scans, chest X-rays and other forms of imaging can help evaluate the heart's size, evaluate for signs of pulmonary oedema, and indicate whether there is fluid around the heart. They are also useful for evaluating the aorta, the major blood vessel which leaves the heart.
An exchange of ions (charged atoms) across the nerve cell membrane sends a depolarizing current towards the end of the nerve cell (cell terminus). When the depolarizing current arrives at the nerve cell terminus, the neurotransmitter acetylcholine (ACh), which is held in vesicles, is released into the space between the two nerves (synapse). It moves across the synapse to the postsynaptic receptors. ACh binds to the receptors and transfers the signal to the target cell, and after a short time, it's destroyed by acetylcholinesterase.
=== Alcohols === Alcohols are commonly used as disinfectants and antiseptics. Alcohols kill vegetative bacteria, most viruses and fungi. Ethyl alcohol, n-propanol and isopropyl alcohol are the most commonly used antimicrobial agents. Methanol is also a disinfecting agent but is not generally used as it is highly poisonous. Escherichia coli, Salmonella, and Staphylococcus aureus are a few bacteria whose growth can be inhibited by alcohols. Alcohols have a high efficiency against enveloped viruses (60–70% ethyl alcohol) 70% isopropyl alcohol or ethanol are highly effective as an antimicrobial agent. In the presence of water, 70% alcohol causes coagulation of the proteins thus inhibiting microbial growth. Alcohols are not quite efficient when it comes to spores. The mode of action is by denaturing the proteins. Alcohols interfere with the hydrogen bonds present in the protein structure. Alcohols also dissolve the lipid membranes that are present in microorganisms. Disruption of the cell membrane is another property of alcohols that aids in cell death. Alcohols are cheap and effective antimicrobials. They are widely used in the pharmaceutical industry. Alcohols are commonly used in hand sanitizers, antiseptics, and disinfectants.
Throughout World War II, the Soviet NKVD's mole Kim Philby had access to high-importance British MI6 intelligence, and passed it to the Soviets. He was able to alert the NKVD about all British intelligence on the Soviets—including what the American OSS had shared with the British about the Soviets. The Soviets believed at the time, and charged throughout the Cold War, that the Americans intentionally delayed the opening of a second front against Germany in order to intervene only at the last minute so as to influence the peace settlement and dominate Europe. Historians such as John Lewis Gaddis dispute this claim, citing other military and strategic calculations for the timing of the Normandy invasion. In the meantime, the Russians suffered heavy casualties, with as many as twenty million dead. Nevertheless, Soviet perceptions (or misconceptions) of the West and vice versa left a strong undercurrent of tension and hostility between the Allied powers. In turn, in 1944, the Soviets appeared to the Allies to have deliberately delayed the relief of the Polish underground's Warsaw Uprising against the Nazi occupation. The Soviets did not supply the Uprising from the air, and for a significant time also refused to allow American air drops. On at least one occasion, a Soviet Air Force fighter shot down a British Royal Air Force plane supplying the Polish insurgents in Warsaw. George Orwell was moved to make a public warning about Soviet postwar intentions. A 'secret war' also took place between the British SOE-backed AK and Soviet NKVD-backed partisans.
Sources: en.wikipedia.org
On 18 December 2008, at the Old Bailey, Napper pleaded guilty to the manslaughter of Rachel Nickell on the grounds of diminished responsibility. Mr Justice Griffith Williams said that Napper would be detained indefinitely at Broadmoor because he was "a very dangerous man".
=== Hormonal regulation === The amyloid-β precursor protein (AβPP), and all associated secretases, are expressed early in development and play a key role in the endocrinology of reproduction – with the differential processing of AβPP by secretases regulating human embryonic stem cell (hESC) proliferation as well as their differentiation into neural precursor cells (NPC). The pregnancy hormone human chorionic gonadotropin (hCG) increases AβPP expression and hESC proliferation while progesterone directs AβPP processing towards the non-amyloidogenic pathway, which promotes hESC differentiation into NPC. AβPP and its cleavage products do not promote the proliferation and differentiation of post-mitotic neurons; rather, the overexpression of either wild-type or mutant AβPP in post-mitotic neurons induces apoptotic death following their re-entry into the cell cycle. It is postulated that the loss of sex steroids (including progesterone) but the elevation in luteinizing hormone, the adult equivalent of hCG, post-menopause and during andropause drives amyloid-β production and re-entry of post-mitotic neurons into the cell cycle.
Anti-Ro and anti-La antibodies, also known as SS-A and SS-B, respectively, are commonly found in primary Sjögren's syndrome, an autoimmune disorder that affects the exocrine glands. The presence of both antibodies is found in 30–60% of Sjögren's syndrome, anti-Ro antibodies alone are found in 50–70% of Sjögren's syndrome and 30% of SLE with cutaneous involvement, and anti-La antibodies are rarely found in isolation. Anti-La antibodies are also found in SLE; however, Sjögren's syndrome is normally also present. Anti-Ro antibodies are also found less frequently in other disorders including autoimmune liver diseases, coeliac disease, autoimmune rheumatic diseases, cardiac neonatal lupus erythematosus and polymyositis. During pregnancy, anti-Ro antibodies can cross the placenta and cause heart block and neonatal lupus in babies. In Sjögren's syndrome, anti-Ro and anti-La antibodies correlate with early onset, increased disease duration, parotid gland enlargement, disease outside the glands and infiltration of glands by lymphocytes. Anti-Ro antibodies are specific to components of the Ro-RNP complex, comprising 45kDa, 52kDa, 54kDa and 60kDa proteins and RNA. The 60kDa DNA/RNA binding protein and 52kDa T-cell regulatory protein are the best characterised antigens of anti-Ro antibodies. Collectively, these proteins are part of a ribonucleoprotein (RNP) complex that associate with the human Y RNAs, hY1-hY5. The La antigen is a 48kDa transcription termination factor of RNA polymerase III, which associates with the Ro-RNP complex.
Unlike wealthy OECD countries, Australian law allows employers to designate employees as "casual", and take away universal rights such as paid holidays or job security in return for a nominal 25% extra pay even if they have lowered market pay in practice to nullify this "casual loading": in 2024, 22% of Australian employees were casual.
Common vervain has been held in high esteem since classical antiquity; it has long been associated with divine and other supernatural forces, and it has an equally long-standing use as a medicinal plant. Herbal capsules are used as a soporific drug in much the same way as for the better known valerian. Verbena officinalis herb has been used in the traditional Austrian medicine internally (as tea or liqueur) for treatment of infections and fever. Medical use of Common Vervain is usually as a herbal tea; Nicholas Culpeper's 1652 The English Physitian discusses folk uses. "Vervain", presumably this species, is one of the original 38 Bach flower remedies, prescribed against "over-enthusiasm". In the modern era, it is sometimes considered a powerful "ally" of poets and writers, as its relaxing effects can relieve writer's block. It cannot be considered safe to use during pregnancy as it might cause miscarriages. While common vervain is not native to North America, it has been introduced there and the Pawnee have adopted it as an entheogen enhancer and in oneiromancy, and is often referred to as the North American version of Calea zacatechichi. In western Eurasia, the term "verbena" or "vervain" usually refers to this, the most widespread and common member of the mostly American genus occurring there. It was called "tears of Isis" in Ancient Egypt, and later on "Juno's tears". In Ancient Greece, it was dedicated to Eos Erigineia.
Sources: en.wikipedia.org
Short stature as a result of chondrodysplasia. Growth plate abnormalities Developmental delays, specifically in language and walking. Difficulty with social interaction. A variety of mild dysmorphic features, with all patients having a prominent nose, thin upper lip, and a wide mouth. Many patients also have ptosis and wide set eyes. ADHD-like symptoms, such as inattentiveness, hyperactivity, and forgetfulness. Difficulty walking, whether from skeletal issues or neurological issues. Many patients have been observed as having mild intellectual disability, microcephaly, hypotonia, and autism. Patients may also have other neurological symptoms such as tremors, unsteady gait, poor reflexes, and seizures. A couple of patients had elevated levels of creatine kinase during infancy that later went down to normal. It's suspected there may be an increased risk of cancer, genitourinary issues, and cardiac issues, but, due to the apparent rareness of VERBAS, it's unclear if there is any connection to VERBAS.
West married fellow scholar Stephanie Pickard in 1960 at Nottingham, after meeting her at a lecture given by Eduard Fraenkel at Corpus Christi College, Oxford, whose seminars he attended. He became a junior research fellow at St John's College from 1960 to 1963. His doctoral thesis, a commentary on Hesiod's Theogony, won the Conington Prize for the best classical dissertation of the year in 1965, and was edited as a printed book the following year. From the mid-sixties, West took especial interest in the relation of Greek literature to the Orient, and over several decades, culminating in his masterpiece The East Face of Helicon (1997), defended his view that Greek literature derives significant influences and inspiration from Near Eastern literature. He took up a position as tutorial fellow at University College, a position he filled from 1963 to 1974. In 1973 he became the second youngest person to be elected a Fellow of the British Academy, at the age of 35. He obtained a chair at Royal Holloway and Bedford New College, which he held from 1974 until 1991, when he became a fellow of All Souls College. West retired formally in 2004, but remained active in All Souls until the end of his life.
Earlier estimates for snakebite vary from 1.2 to 5.5 million, with 421,000 to 2.5 million being envenomings, and causing 20,000 to 125,000 deaths. More recent modelling estimates that in 2019, about 63,400 people died globally from snakebite, with 51,100 of these deaths happening in India. Since reporting is not mandatory in much of the world, the data on the frequency of snakebites is not precise. Many people who survive bites have permanent tissue damage caused by venom, leading to disability. Most snake envenomings and fatalities occur in South Asia, Southeast Asia, and sub-Saharan Africa, with India reporting the most snakebite deaths of any country. Available evidence on the effect of climate change on the epidemiology of snakebite is limited but it is expected that there will be a geographic shift in the risk of snakebite: northwards in North America and southwards in South America and Mozambique, and increase in the incidence of bite in Sri Lanka. Most snakebites are caused by non-venomous snakes. Of the roughly 3,000 known species of snake found worldwide, only 15% are considered dangerous to humans. Snakes are found on every continent except Antarctica. The most diverse and widely distributed snake family, the colubrids, has approximately 700 venomous species, but only five genera—boomslangs, twig snakes, keelback snakes, green snakes, and slender snakes—have caused human fatalities. Worldwide, snakebites occur most frequently in the summer season when snakes are active and humans are outdoors.
HLA-DM (human leukocyte antigen DM) is an intracellular protein involved in the mechanism of antigen presentation on antigen presenting cells (APCs) of the immune system. It does this by assisting in peptide loading of major histocompatibility complex (MHC) class II membrane-bound proteins. HLA-DM is encoded by the genes HLA-DMA and HLA-DMB. HLA-DM is a molecular chaperone that works in lysosomes and endosomes in cells of the immune system. It works in APCs like macrophages, dendritic cells, and B cells by interacting with MHC class II molecules. HLA-DM protects the MHC class II molecules from breaking down, and regulates which proteins or peptides bind to them as well. This regulates how and when a peptide acts as an antigen initiating an immune response. Thus, HLA-DM is necessary for the immune system to respond effectively to a foreign invader. Impairment in HLA-DM function can result in immunodeficiency and autoimmune diseases.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.